Shopping Cart
- Remove All
Your shopping cart is currently empty
Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $332 | 2-4 weeks | |
| 5 mg | $996 | 2-4 weeks | |
| 10 mg | $1,570 | 2-4 weeks |
| Description | Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naïve T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2]. |
| In vivo | Tamtuvetmab, administered intravenously at a concentration of 5 mg/mL and volumes ranging from 7.5 to 30 mL over 15 to 30 minutes, demonstrates in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). However, it is associated with adverse effects including vomiting, weight loss, diarrhea, lethargy, reduced appetite, and anorexia [1]. |
| Synonyms | AT-005, AT005 |
| Cas No. | 1608122-71-9 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.